OneOme, the company behind the OneOme RightMed pharmacogenomics test, recently delivered a statement about how DNA has the power to minimize medication trial and error and help people with heart conditions improve their cardiovascular treatments.
“Figuring out which heart medication will work best for you through trial and error is expensive, time-consuming and potentially dangerous," OneOme CEO Paul Owen said in a statement. "The RightMed pharmacogenomic test minimizes those risks by using your DNA to predict how heart medications will work for an individual patient. This Heart Month, we encourage those who are suffering from heart conditions to speak with their healthcare provider about using OneOmes RightMed test to make their prescriptions personal.
The company noted that its product was co-developed with the Mayo Clinic. The test delivers a cost-effective, comprehensive, personalized pharmacogenomic analysis of 22 genes for $249. Upon conclusion of the test, health care providers will have information to administer more personalized treatment decisions.
Cardiovascular disease is the leading cause of death in the United States according to the Centers for Disease Control and Prevention.